 BioMarin Pharmaceutical Inc NASDAQ: BMRN faces another setback in its gene therapy development program after the FDA placed the phenylketonuria PKU gene therapy trial on hold. The Phase 12 Phearless study is evaluating BMN 307, an AAV5-phenylalanine hydroxylase PAH gene therapy for PKU. 